Ruthenium-based chemotherapeutics: Are they ready for prime time?

Keyphrases

• Ruthenium 100%
• Ruthenium Compounds 60%
• Further Development 20%
• Tumor Cells 20%
• Cancer Metastasis 20%
• Drug Action 20%
• Potential Identification 20%
• Antitumor Agents 20%
• Mechanism of Action 20%
• Platinum Resistance 20%
• Primary Tumor 20%
• Clinical Testing 20%
• Chemical Properties 20%
• Minimal Impact 20%
• Preclinical Data 20%
• Human Trials 20%
• Kinase Inhibition 20%
• Cis-platinum 20%
• Active State 20%
• Combination Strategy 20%
• Biochemical Features 20%
• Drug-resistant Tumor 20%
• Neoplastic Tissue 20%
• Antineoplastic Agents 20%
• Pharmacodynamic Biomarker 20%
• Transition Metal Complexes 20%
• Anti-metastatic Agent 20%
• Rational Combinations 20%
• PIM Kinase 20%
• Ruthenium Drugs 20%
• KP1019 20%
• NAMI-A 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Ruthenium Derivative 100%
• Neoplasm 66%
• Pharmacodynamics 33%
• Cisplatin 33%
• Clinical Study 33%
• Biological Marker 33%
• Coordination Compound 33%
• Antimetastatic Agent 33%
• Protein Kinase Pim 1 33%
• Primary Tumor 33%